FierceBiotech4h
BridgeBio's KRAS-focused cancer spinout backs SPAC as path to Nasdaq
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...
FierceBiotech5h
Praxis flouts phase 3 futility finding, forging ahead with tremor trial despite interim setback
Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after ...
FierceBiotech5h
Research reveals ‘ticking DNA clock’ behind Huntington’s disease
Huntington’s disease was long thought to be caused by the slow buildup of a toxic protein, but new research has reveale | ...
FierceBiotech5h
Chutes & Ladders—Private equity firms take over bluebird's nest
Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of private equity firms Carlyle and SK Capital in a ...
FierceBiotech7h
Mission changes, shuttering lab to focus on clinical assets
AbbVie-partnered Mission Therapeutics is tweaking its trajectory, closing a preclinical laboratory in the U.K. to focus on ...
FierceBiotech7h
Eli Lilly feels Magnet's pull with molecular glue deal potentially worth $1.25B
The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.65 billion ...
FierceBiotech9h
Nxera sells APAC license to lupus drug to Viatris for $10M upfront
Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront.